老年非瓣膜性心房颤动患者抗凝治疗的疗效性及安全性评价

Efficacy and safety of anticoagulant therapy in elderly patients with nonvalvular atrial fibrillation

目的:研究年龄≥75岁的非瓣膜性心房颤动患者抗凝治疗的疗效及安全性。方法:2017年1月-2018年12月收治老年非瓣膜性心房颤动患者196例,将坚持服用新型口服抗凝药物利伐沙班或华法林、且国际标准化比值(INR)达标患者设为抗凝组,其余患者设为未抗凝组。比较两组1年内血栓栓塞事件、出血事件及因血栓栓塞或出血致死致残情况。结果:抗凝组栓塞率低于未抗凝组,差异有统计学意义(P<0.05);抗凝组出血或栓塞致死致残率低于未抗凝组,差异有统计学意义(P<0.05)。结论:抗凝治疗对老年非瓣膜性心房颤动患者的疗效确切,且具有安全性。

Objective:To explore the efficacy and safety of anticoagulant therapy in elderly patients over 75 years old with nonvalvular atrial fibrillation.Methods:From January 2017 to December 2018,196 elderly patients with nonvalvular atrial fibrillation were selected,patients who insisted on taking new oral anticoagulant drugs rivaroxaban or warfarin and whose INR reached the standard were set as the anticoagulant group,and the rest patients were set as the non anticoagulant group.We compared the thromboembolic events,bleeding events and death and disability due to thromboembolism or hemorrhage in the two groups within one year.We compared the thromboembolic events,bleeding events and death and disability due to thromboembolism or hemorrhage in the two groups within one year.Results:The embolism rate of anticoagulant group was lower than that of non anticoagulant group,the difference was statistically significant(P<0.05).In the anticoagulant group,the mortality and disability rate of bleeding was significantly lower than mortality and disability rate of embolism in the non anticoagulant group,the difference was statistically significant(P<0.05).Conclusion:Anticoagulant therapy is effective and safe for elderly patients with nonvalvular atrial fibrillation.